Intracutaneous Reactivity Testing of Silver-Containing Collagen Wound Dressings: Standards, Methods,

The intracutaneous reactivity test is a fundamental biocompatibility study for silver-containing collagen wound dressings that contact breached or compromised skin, evaluating whether extractable substances—including released silver species—provoke localized tissue irritation. Conducted by accredited third-party laboratories in accordance with ISO 10993-23, ISO 10993-12, and the corresponding GB/T 16886 series, the test provides essential evidence for medical device registration dossiers and biological safety files. This article details the sample preparation, testing items, procedural methods, scoring criteria, and typical applications of the intracutaneous reactivity experiment for these advanced antimicrobial dressings.

Technical Overview

Silver-containing collagen wound dressings combine the moisture-retention, hemostatic, and cellular-scaffolding properties of collagen with the broad-spectrum antimicrobial action of silver, delivered as ionic silver, silver sulfadiazine, or nanocrystalline silver. These products are indicated for moderately to highly exuding wounds, diabetic foot ulcers, pressure injuries, venous leg ulcers, and colonized or infected wound sites, where they remain in contact with breached or compromised skin for extended durations.

Under ISO 10993-1, such dressings are classified as surface medical devices contacting breached or compromised skin, and irritation is a mandatory endpoint of the biological evaluation. The intracutaneous reactivity test (also referred to as the intracutaneous irritation test) determines whether substances leached from the dressing under controlled extraction conditions elicit localized irritation when injected into rabbit skin. Because the extract is introduced directly into the dermis, the method is generally more sensitive than epidermal application and serves as an effective screening study for extractable-mediated irritation hazards.

The test procedure is specified in ISO 10993-23:2021, which superseded the intracutaneous test formerly described in ISO 10993-10, while sample preparation is governed by ISO 10993-12. In China, equivalent requirements are established in GB/T 16886.10 and GB/T 16886.12, and ASTM F749 describes a comparable rabbit intracutaneous injection practice. Animal welfare and study justification follow ISO 10993-2.

Testing Samples

Finished Product Specimens

Representative specimens are taken from the sterilized dressing in its final packaging. The material is cut into pieces, and the exposed surface area or mass is measured to establish the extraction ratio. In accordance with ISO 10993-12, typical surface-area-to-volume ratios include 6 cm²/mL for dressings with a thickness of 0.5 mm or less and 3 cm²/mL for thicknesses between 0.5 mm and 1.0 mm. For thick, porous, or highly absorbent dressings such as collagen foams and hydrocolloid composites, mass-based ratios in the range of 0.1 g/mL to 0.2 g/mL are commonly applied.

Extraction Media

• Polar medium: 0.9% sodium chloride injection (physiological saline) or serum-free culture medium, simulating the aqueous wound environment and extracting hydrophilic collagen degradation products, salts, and water-soluble processing residues.
• Non-polar medium: pharmacopoeial-grade sesame oil or cottonseed oil, which extracts lipophilic substances such as certain silver complexes, residual crosslinking agents, plasticizers, and lubricants.
• Blank controls: each extraction medium without the test article, subjected to identical extraction conditions, temperature, and duration.

Extraction Conditions

Extraction is preferably performed at 37 ± 1 °C for 24 ± 2 h to simulate actual clinical contact conditions. Alternative exaggerated conditions permitted by ISO 10993-12 include 50 ± 2 °C for 72 ± 2 h, 70 ± 2 °C for 24 ± 2 h, or 121 ± 2 °C for 1 ± 0.2 h, provided the higher temperature does not degrade or transform the material in a way that misrepresents clinical exposure. Gentle agitation may be used, extracts are inspected for pH shift, discoloration, or precipitation, and they are administered promptly after preparation.

Testing Items

The core testing item is intracutaneous reactivity, which comprises the following evaluations:

• Erythema and eschar formation at intradermal injection sites.
• Edema formation at intradermal injection sites.
• Calculation of the Primary Irritation Index (PII) separately for polar and non-polar extracts.
• Comparative evaluation of test extract responses against corresponding blank extraction media controls.

Observations and scoring are performed at 24 h, 48 h, and 72 h after injection. Records also document any additional lesions such as necrosis, blanching, or grey-to-brown metallic discoloration that may indicate localized silver deposition.

Testing Methods

Animal Model and Preparation

Healthy adult albino rabbits, typically New Zealand White with a body weight of at least 2 kg, are used, with a minimum of three animals per study. Animals are acclimatized before the test, and the dorsal fur is closely clipped 4 h to 24 h prior to injection. Only animals with intact, non-irritated skin are selected. The study design, animal numbers, and humane endpoints comply with ISO 10993-2 and the relevant national laboratory animal welfare regulations.

Intracutaneous Injection Procedure

On one side of the vertebral column, 0.2 mL of the test extract is injected intradermally at five sites spaced approximately 2 cm apart. The contralateral side receives 0.2 mL of the corresponding blank medium at five matching sites. Both the polar and non-polar extracts are evaluated on each animal, for example in cranial and caudal regions. Injection sites are inspected immediately after dosing to confirm correct intradermal delivery, evidenced by a characteristic bleb; if a site is compromised by improper injection, an adjacent site is used.

Scoring System

Erythema and eschar formation is graded as follows:

• 0 — No erythema.
• 1 — Very slight erythema, barely perceptible.
• 2 — Well-defined erythema.
• 3 — Moderate to severe erythema.
• 4 — Severe erythema (beet redness) to slight eschar formation preventing accurate grading of erythema.

Edema formation is graded as follows:

• 0 — No edema.
• 1 — Very slight edema, barely perceptible.
• 2 — Well-defined edema with edges clearly raised.
• 3 — Moderate edema, raised approximately 1 mm.
• 4 — Severe edema, raised more than 1 mm and extending beyond the exposure area.

Calculation and Interpretation

The erythema and edema scores are summed for each site at each observation interval, and the Primary Irritation Index is calculated as the aggregate irritation score divided by the total number of scoring observations, typically five sites read at three time points for three animals. Interpretation bands are 0.00 to 0.4 as negligible irritation, 0.5 to 1.9 as slight, 2.0 to 4.9 as moderate, and 5.0 to 8.0 as severe. The requirement is met when the response to the test extract is not greater than that of the blank control; where the oil blank itself elicits a reaction, the test scores are assessed relative to the control scores as specified in the standard.

For silver-containing dressings, grey-brown discoloration at injection sites caused by deposited silver must be distinguished from true erythema. Interpretation is strengthened by supporting chemical characterization of leachables and silver release kinetics in line with ISO 10993-18, together with toxicological risk assessment in line with ISO 10993-17.

Applications

Intracutaneous reactivity data support multiple regulatory and development objectives throughout the product lifecycle:

• National medical device registration submissions, including biological evaluation chapters of dossiers filed with authorities such as NMPA in China and the US FDA.
• CE technical documentation and post-market safety files under the EU MDR.
• ISO 10993-1 gap analysis and integrated biological safety files compiled by accredited third-party laboratories.
• Research and development screening of collagen sources, silver loading levels, crosslinking residues, and sterilization methods.
• Change control justification for modifications to materials, suppliers, manufacturing processes, or packaging.

When the dressing family shares common materials of construction and manufacturing conditions, a documented justification may allow the intracutaneous reactivity study to cover multiple configurations, reducing redundant animal testing in accordance with the 3Rs principles.

FAQ

Which standards govern the intracutaneous reactivity test for silver-containing collagen wound dressings?

The primary standard is ISO 10993-23:2021, which absorbed the intracutaneous reactivity method formerly published in ISO 10993-10. Sample preparation and extraction follow ISO 10993-12, animal welfare follows ISO 10993-2, and in China the harmonized equivalents are GB/T 16886.10 and GB/T 16886.12. ASTM F749 describes a broadly similar rabbit intracutaneous injection practice and may be referenced where ASTM frameworks are preferred.

Why must both polar and non-polar extracts be tested?

Collagen and most hydrophilic excipients partition into aqueous media, whereas certain silver species, lipid-soluble additives, residual monomers, and processing aids partition into oil. Evaluating both polar and non-polar extracts ensures that hydrophilic and lipophilic leachables are each assessed for their local irritation potential, providing comprehensive coverage of the extractable profile.

What are the acceptance criteria for a passing result?

The study is considered valid only when blank control reactions remain minimal, with oil blank responses accounted for in the comparative evaluation. The test sample meets the requirement when the irritation response to its extract is not greater than the corresponding blank control response; in practice, a Primary Irritation Index in the negligible band of 0.00 to 0.4 is widely accepted as a clear pass, provided the control data confirm test validity.

How does the silver component influence the test outcome?

Released silver ions possess inherent antimicrobial and cytotoxic activity, and elevated local concentrations in the extract can increase the likelihood of a mild irritation response. In addition, deposited silver may cause grey-brown discoloration of the injection sites that must not be misread as erythema. Results are therefore interpreted alongside quantitative silver release data and a toxicological risk assessment of the leachables.

How many animals are used and how long does the study take?

A standard study uses three rabbits. After acclimatization and fur clipping, extraction is completed, injections are performed, and observations continue through 72 hours. Including extraction, in-life phases, and report preparation, the complete study is typically finalized within two to four weeks, subject to laboratory scheduling.

Can the intracutaneous reactivity test replace other biocompatibility studies?

No. The intracutaneous test addresses only the irritation potential of device extracts. Sensitization testing per ISO 10993-10:2021, cytotoxicity per ISO 10993-5, and material-mediated chemical characterization per ISO 10993-18 remain distinct endpoints. The complete evaluation set for a silver-containing collagen wound dressing is defined case by case through the risk management process described in ISO 10993-1.